Stock analysts at StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their price objective on shares of Regulus Therapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, April 21st.
Regulus Therapeutics Stock Down 2.9 %
NASDAQ:RGLS opened at $1.33 on Wednesday. The company has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.37. Regulus Therapeutics has a 1-year low of $0.76 and a 1-year high of $3.40.
Institutional Investors Weigh In On Regulus Therapeutics
A number of large investors have recently modified their holdings of the business. Federated Hermes Inc. acquired a new position in Regulus Therapeutics during the first quarter worth about $8,656,000. Vanguard Group Inc. grew its holdings in shares of Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 648,121 shares during the period. Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 111,100 shares during the period. Northern Trust Corp boosted its holdings in Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Regulus Therapeutics in the 3rd quarter valued at about $54,000. Hedge funds and other institutional investors own 55.47% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.